Singapore Clinical Trial: A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Participants With EGFR-mutated Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib and Chemotherapy Combination Treatment (GROVE)

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Participants With EGFR-mutated Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib and Chemotherapy Combination Treatment (GROVE)'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): Curie Oncology (Farrer) Icon Cancer Centre National Cancer Centre National University Hospital OncoCare Cancer Centre (Gleneagles) Tan Tock Seng Hospital

Trial Status: NA

Principal Investigator(s): Dr Toh Chee Keong Dr Patricia Kho Dr Teh...